Support References

Adoptive cell therapy for the treatment of patients with metastatic melanoma. Rosenberg SA, Dudley ME, Curr Opin Immunol. 2009 Apr;21(2):233-40. Epub 2009 Mar 21

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. Dudley ME, et al., J Clin Onc 26:5233-5239 (2008)

Current immunotherapeutic strategies in pancreatic cancer. Plate JM, et al., Surg Oncol Clin N Am. 16:919-43 (2007)

Objective clinical regression of metastatic breast cancer in disparate sites after use of whole-cell vaccine genetically modified to release sargramostim. Wiseman CL, Kharazi A. Breast J. 12:475-80 (2006)

M-Vax: an autologous, hapten-modified vaccine for human cancer. Berd D. Expert Rev Vaccines. 3:521-7 (2004)

Immunological effects of granulocyte-macrophage colony-stimulating factor and autologous tumor vaccine in patients with renal cell carcinoma. Schwaab T, et al., J Urol. 171:1036-42 (2004)

Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Jocham D, et al., Lancet. 363:594-599 (2004)

Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. Neumunaitis J, et al., J Natl Cancer Inst. 96:326-331 (2004)

Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer. Chang AE, et al., J Clin Oncol 21:884-90 (2003)

Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. Salgia R, et al., J Clin Oncol. 21:624-30 (2003)

Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes. Sloan AE, Neurosurg Focus. 2000 Dec 15;9(6):e9.

A pilot study of autologous cancer cell vaccination and cellular immunotherapy using anti-CD3 stimulated lymphocytes in patients with recurrent grade III/IV astrocytoma. Wood GW, Holladay FP, et al., J Neurooncol. 48:113-20 (2000)

Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies. Nelson DS, et al., Cancer Chemother Pharmacol. 46 Suppl:S67-72 (2000)

Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Simons JW, et al., Cancer Res.59:5160-8 (1999)

Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Vermorken JB, et al. Lancet. 353:345-50 (1999)

Autologous, hapten-modified vaccine as a treatment for human cancers. Berd D, et al., Semin Oncol. 25:646-53 (1998)

Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Soiffer R, et al., Proc Natl Acad Sci USA. 95:13141-6 (1998)

Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Simons JW, et al., Cancer Res. 57:1537-46 (1997)

Adoptive transfer of anti-CD3-activated CD4+ T cells plus cyclophosphamide and liposome-encapsulated interleukin-2 cure murine MC-38 and 3LL tumors and establish tumor-specific immunity. Saxton ML, et al., Blood. 89:2529-2536 (1997)

Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. Chang AE, et al., J Clin Oncol. 15:796-807 (1997)

A phase I study of vaccination with autologous, irradiated melanoma cells engineered to secrete human granulocyte-macrophage colony stimulating factor. Dranoff G, et al., Hum Gene Ther. 8:111-23 (1997)

Autologous tumor cell vaccination combined with adoptive cellular immunotherapy in patients with grade III/IV astrocytoma. Holladay FP, et al., J Neurooncol. 27:179-89 (1996)

Phase I study of non-replicating autologous tumor cell injections using cells prepared with or without GM-CSF gene transduction in patients with metastatic renal cell carcinoma. Berns AJ et al., Hum Gene Ther. 6:347-68 (1995)

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Dranoff G, et al., Proc Natl Acad Sci USA. 90:3539-43 (1993)

Delayed cutaneous hypersensitivity to autologous tumor cells in colorectal cancer patients immunized with an autologous tumor cell: Bacillus Calmette-Guérin vaccine. Hoover HC Jr., et al., Proc Natl Acad Sci USA. 44:1671-6 (1984)

High-dose Chemotherapy and Adoptive Immunotherapy in the Treatment of Recurrent Pediatric Brain Tumors. Peres E, et al. E. Neuropediatrics. 39:151-6 (2008)